Tenax Therapeutics (TENX)
NASDAQ:TENX
Want to see TENX full AI Analyst Report?
TENX Stock Chart & Stats
$14.45
<$0.01(0.16%)
At close: 4:00 PM EST
$14.45
<$0.01(0.16%)
Day’s Range― - ―
52-Week Range$5.34 - $18.38
Previous CloseN/A
Volume25.45K
Average Volume (3M)658.95K
Market Cap
$284.61M
Enterprise Value$85.38M
Total Cash (Recent Filing)$118.75M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Aug 18, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding26,525,160
10 Day Avg. Volume797,055
30 Day Avg. Volume658,947
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)4.92
Price to Sales (P/S)0.00
P/FCF Ratio-13.35
Enterprise Value/Market Cap0.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$36.50Price Target Upside152.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA near-zero debt profile and materially increased equity/assets provide structural financial flexibility. This reduces interest burden and insolvency risk, giving management time and optionality to advance registrational programs without immediate refinancing pressure, supporting multi-quarter execution.
Experienced CFO AddedAdding a seasoned biotech finance executive strengthens capital markets access, deal execution and strategic financing capabilities. His experience and incentive-linked awards align long-term shareholder outcomes and improve probability of securing non-dilutive or structured funding for pivotal trials.
Focused Clinical PipelineConcentrated focus on pulmonary hypertension and a potential first-in-class asset creates meaningful upside if clinical success is achieved. Specialization can yield competitive differentiation, pricing power in niche markets, and attractive licensing or partnership opportunities over a multi-quarter horizon.
Bears Say
Pre-revenue With Widening LossesPersistent pre-revenue status combined with materially expanding net losses creates a structural funding requirement. Without product sales, the company must rely on capital markets or partners, increasing dilution and execution risk for registrational programs over the coming quarters.
High And Worsening Cash BurnSteadily increasing operating cash outflows erode runway and amplify financing needs. This trend raises the likelihood of near-term capital raises or partnerships that may be dilutive or constrain strategic choices, creating sustained execution risk until revenue generation begins.
Very Small Internal TeamA four-person employee base implies heavy reliance on external vendors, CROs and partners for trials and commercialization planning. Limited internal capacity can slow decision-making, increase program management risk, and make scaling operations more costly and time-consuming over multiple quarters.
Tenax Therapeutics News
TENX FAQ
What was Tenax Therapeutics’s price range in the past 12 months?
Tenax Therapeutics lowest stock price was $5.34 and its highest was $18.38 in the past 12 months.
What is Tenax Therapeutics’s market cap?
Tenax Therapeutics’s market cap is $284.61M.
When is Tenax Therapeutics’s upcoming earnings report date?
Tenax Therapeutics’s upcoming earnings report date is Aug 18, 2026 which is in 67 days.
How were Tenax Therapeutics’s earnings last quarter?
Tenax Therapeutics released its earnings results on May 12, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.397 by $0.047.
Is Tenax Therapeutics overvalued?
According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued.
Does Tenax Therapeutics pay dividends?
Tenax Therapeutics does not currently pay dividends.
What is Tenax Therapeutics’s EPS estimate?
Tenax Therapeutics’s EPS estimate is -0.39.
How many shares outstanding does Tenax Therapeutics have?
Tenax Therapeutics has 26,525,160 shares outstanding.
What happened to Tenax Therapeutics’s price movement after its last earnings report?
Tenax Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.397. Following the earnings report the stock price went up 1.841%.
Which hedge fund is a major shareholder of Tenax Therapeutics?
Currently, no hedge funds are holding shares in TENX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenax Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.50 (152.60% Upside)
$36.50 (152.60% Upside)
Blogger Sentiment
Neutral
TENX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.1%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.77%
12-Months-Change
Fundamentals
Return on Equity
-56.32%
Trailing 12-Months
Asset Growth
9.92%
Trailing 12-Months
Company Description
Tenax Therapeutics
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
TENX Stock 12 Month Forecast
Average Price Target
$36.50
▲(152.60% Upside)
Technical Analysis
Tempest Therapeutics
―
Relmada Therapeutics
―
VYNE Therapeutics
―
Longeveron
―
Calidi Biotherapeutics
―
Ownership Overview
0.16% Insiders
11.96% Mutual Funds
42.80% Other Institutional Investors
43.71% Public Companies and
Individual Investors